Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: J Neurooncol. 2009 Jun 28;96(2):219–230. doi: 10.1007/s11060-009-9950-0

Fig. 1.

Fig. 1

The immunohistochemical profile of patient A103 demonstrates a strong diffuse immunoreactivity for EGFR wild type, b 30% reactivity for PTEN that correlates with PTEN loss; c negative reactivity for EGFRvIII, d diffuse reactivity for pAKT, and e rare cells exhibiting pS6 immunoreactivity with a positive internal neuronal control (arrow). The internal bar represents 50 microns